L3VLUP
ProSign in

ANGO · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ANGOVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ANGO
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterANGOVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 20211 holders, $10m31 holders, $15.4bn
Q2 20211 holders, $19m30 holders, $12.7bn
Q3 2021none listed holders, n.a.35 holders, $10.1bn
Q4 20211 holders, $21m28 holders, $12.4bn
Q1 20221 holders, $25m23 holders, $16.1bn
Q2 20221 holders, $18m25 holders, $18.1bn
Q3 20221 holders, $13m22 holders, $18.4bn
Q4 2022none listed holders, n.a.28 holders, $18.4bn
Q1 20231 holders, $388k26 holders, $21.4bn
Q2 20231 holders, $391k27 holders, $24.7bn
Q3 20231 holders, $6.0m33 holders, $24.3bn
Q4 20233 holders, $13m32 holders, $28.6bn
Q1 20241 holders, $5.9m31 holders, $29.8bn
Q2 20242 holders, $7.5m29 holders, $33.4bn
Q3 20241 holders, $3.1m27 holders, $33.5bn
Q4 20241 holders, $3.8m26 holders, $28.5bn
Q1 20252 holders, $4.4m21 holders, $35.4bn
Q2 20252 holders, $3.9m21 holders, $32.3bn
Q3 20253 holders, $34m22 holders, $25.9bn
Q4 20252 holders, $5.6m26 holders, $31.8bn
Q1 20262 holders, $5.4m25 holders, $31.8bn
Q2 20262 holders, $6.0m26 holders, $34.6bn
ANGO

Angiodynamics Inc

Holders
3
Reported value
$13m
Buyers
2
Sellers
1

Breadth +1 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ANGO (1)

ExodusPoint Capital Management LP

Only VRTX (30)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →